ArticleJournal of cancer research and clinical oncology2025
High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimThis study characterizes the functional effects and clinical characteristics of high PER1 mRNA and high PER1 protein expression in treatment resistant lung adenocarcinoma.
methodsHBEC3-KT cells were modified by STK11 CRISPR knockout and A549 cells by LKB1 addback using stable transfection. RNA sequencing and western blot were used to profile gene and protein expression. Pooled siRNA knockdown of PER1 was used to assess impacts on cell proliferation and 3D invasion. Human lung adenocarcinoma data were analyzed using cBioPortal.
resultsPER1 mRNA and protein are upregulated in STK11-mutant lung adenocarcinoma tumors and STK11-knockout human bronchial epithelial cells (HBEC3-KT). Addback of wildtype LKB1 in A549 lung cancer cells is sufficient to decrease PER1 protein levels. Knockdown of PER1 decreased cell growth, proliferation, and 3D invasion in LKB1-deficient cell models. High PER1 expression in lung cancer patients correlates with LKB1 mutation status, decreased expression of the gene that encodes PD-L1, and altered hypoxia and immune and stromal ESTIMATE scores.
conclusionPER1 has oncogenic activity in LKB1-mutant lung cancer cells and high PER1 expression in lung adenocarcinoma patients may represent an independent biomarker of resistance to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.